Detalles de la búsqueda
1.
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
Diabetes Obes Metab
; 24(8): 1578-1587, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35478433
2.
Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
Nephrol Dial Transplant
; 35(Suppl 1): i33-i42, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32003836
3.
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
Diabetes Obes Metab
; 21(12): 2667-2673, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31407856
4.
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.
Curr Diab Rep
; 18(5): 27, 2018 03 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29589183
5.
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
Nephrol Dial Transplant
; 33(11): 2005-2011, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29370424
6.
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Diabetes Obes Metab
; 20(8): 1988-1993, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29573529
7.
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
Nephrol Dial Transplant
; 33(7): 1280, 2018 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29762740
8.
The Value of Pre-Ablative I-131 Scan for Clinical Management in Patients With Differentiated Thyroid Carcinoma.
Front Endocrinol (Lausanne)
; 12: 655676, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34122334
9.
Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease.
Clin Pharmacokinet
; 60(4): 517-525, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33587286
10.
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Lancet Diabetes Endocrinol
; 8(7): 582-593, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32559474
11.
Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors.
J Clin Med
; 8(6)2019 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-31159350
Resultados
1 -
11
de 11
1
Próxima >
>>